Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2-amplified esophageal adenocarcinomas exhibit an activated metabolic and immunosuppressive phenotype with multiple potential therapeutic targets.

BMC cancer - 26 Nov 2025

Knipper Karl, Bruns Christiane J, Popp Felix C, Schmidt Thomas, Grothey Bastian, Quaas Alexander, Lyu Su Ir

Abstract excerpt

BACKGROUND: A complete response following neoadjuvant therapy occurs only in a fraction of patients with esophageal adenocarcinoma (EAC). Further targeted treatment options are needed to improve treatment response and patient survival. Mouse double minute 2 homolog (MDM2) is a known oncogene. It is currently under investigation as a potential therapeutic target. However, initial findings have not been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Gene Amplification

Share to Gene Expression Regulation, Neoplastic

Share to In Situ Hybridization, Fluorescence

Share to Phenotype

Share to Proto-Oncogene Proteins c-mdm2

Source

Open in PubMed Open full text

Identifiers

PMID: 41299419
DOI: 10.1186/s12885-025-15367-3
PMCID: PMC12690831

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2-amplified esophageal adenocarcinomas exhibit an activated metabolic and immunosuppressive phenotype with multiple potential therapeutic targets.PMID 41299419Read ↗

MDM2 gene amplification in esophageal carcinoma.Semantic proximity Read ↗

MDM2 inhibitors in sarcomas: results and next stepsSemantic proximity Read ↗

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.Semantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

The MDM2 gene amplification databaseSemantic proximity Read ↗

Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.Semantic proximity Read ↗

Current evidence on the relationship between murine double minute 2 T309G polymorphism and esophageal cancer susceptibility.Semantic proximity Read ↗

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumorsSemantic proximity Read ↗

Benzydamine, a CDK2 Kinase Inhibitor, Suppresses The Growth of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo.Semantic proximity Read ↗

mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.Semantic proximity Read ↗

TGM2: a cell surface marker in esophageal adenocarcinomas.Semantic proximity Read ↗

Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.